teclistamab
Selected indexed studies
- Teclistamab in Relapsed or Refractory Multiple Myeloma. (N Engl J Med, 2022) [PMID:35661166]
- Teclistamab: Mechanism of action, clinical, and translational science. (Clin Transl Sci, 2024) [PMID:38266057]
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. (N Engl J Med, 2026) [PMID:41363801]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. (2025) pubmed
- Teclistamab in Relapsed or Refractory Multiple Myeloma. (2022) pubmed
- Teclistamab: Mechanism of action, clinical, and translational science. (2024) pubmed
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. (2026) pubmed
- Teclistamab. (2006) pubmed
- Teclistamab. (2012) pubmed
- Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus. (2024) pubmed
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. (2021) pubmed
- Teclistamab: First Approval. (2022) pubmed
- Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. (2024) pubmed